JNJ · Johnson & Johnson
$265.58
-0.29% last session
End-of-day data · close of 2026-09-11
Market cap
$640B
Enterprise value
$668B
Trailing P/E
30.8
Forward P/E
21.3
Dividend yield
2.0%
Beta
0.24
Avg volume
8M
Employees
138K
Daily Change %
-0.29%
5 Days Change
-3.23%
10 Days Change
-1.78%
30 Days Change
2.61%
60 Days Change
3.84%
Month to Day Change
-1.78%
Year to Day Change
30.77%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — JNJ
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
HSBC
Buy$320
+20.1% vs priceUBS
Buy$320
+20.1% vs priceWells Fargo
Overweight$282
+5.9% vs priceRBC Capital
Outperform$287
+7.8% vs priceMorgan Stanley
Overweight$294
+10.4% vs priceBank of America
Neutral$263
-1.3% vs priceCitigroup
Buy$298
+11.9% vs priceBarclays
Equal-Weight$255
-4.3% vs priceJP Morgan
Neutral$250
-6.1% vs priceGoldman Sachs
Buy$240
-9.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | HSBC | Maintains | Buy | $290 → $320 |
| 2026-09-02 | UBS | Maintains | Buy | $280 → $320 |
| 2026-08-06 | Guggenheim | Maintains | Buy | $270 → $287 |
| 2026-08-03 | Wells Fargo | Maintains | Overweight | $272 → $282 |
| 2026-07-17 | Guggenheim | Reiterates | Buy | $270 |
| 2026-07-16 | Raymond James | Maintains | Outperform | $258 → $265 |
| 2026-07-16 | RBC Capital | Reiterates | Outperform | $287 |
| 2026-07-16 | Wells Fargo | Maintains | Overweight | $263 → $272 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.5% above the 50-day MA ($261.76).
- Price vs 200-day MA: Trading 13.1% above the 200-day MA ($234.88).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.11) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($278.43).
JNJ Price Chart
Loading chart for JNJ…
Fundamentals
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.